Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AJ7T | ISIN: NL0011821392 | Ticker-Symbol: G14
Tradegate
20.01.25
19:06 Uhr
22,260 Euro
-0,080
-0,36 %
1-Jahres-Chart
SIGNIFY NV Chart 1 Jahr
5-Tage-Chart
SIGNIFY NV 5-Tage-Chart
RealtimeGeldBriefZeit
22,24022,32008:30
22,24022,32008:30
GlobeNewswire (Europe)
437 Leser
Artikel bewerten:
(2)

Signify publishes comparable financials for 2023 and Q1 2024 following implementation of new organizational structure

Finanznachrichten News

June 14, 2024

Signify publishes comparable financials for 2023 and Q1 2024 following implementation of new organizational structure1

Eindhoven, the Netherlands - Signify(Euronext: LIGHT), the world leader in lighting, has published its quarterly comparable financials for the year 2023 and Q1 2024. Following the implementation of Signify's new organizational structure on April 1, the company has established four verticalized businesses with full profit and loss responsibility2. Each of these four businesses will be fully responsible for its end-to-end processes including offer development, manufacturing, and sales & marketing.

The Professional business offers LED lamps, luminaires, connected lighting systems and services to customers in the professional segment. The Professional business is the combination of the former Digital Solutions division and Professional LED lamps and luminaires, which was formerly part of the Digital Products division.

Reflecting this shift and the reallocation of central costs to the businesses, the Professional business recorded sales of EUR 4,254 million with an Adjusted EBITA of EUR 412 million and an Adjusted EBITA margin of 9.7% for the year 2023. In Q1 2024, the Adjusted EBITA margin decreased from 7.9% to 7.4% year on year.

The Consumer business offers LED lamps, luminaires, and connected products, including Philips Hue and WiZ, to customers in the consumer segment. The Consumer business was formerly part of the Digital Products division alongside Professional LED lamps and luminaires and the OEM business.

Reflecting this shift and the reallocation of central costs to the businesses, the Consumer business recorded sales of EUR 1,342 million with an Adjusted EBITA of EUR 120 million and an Adjusted EBITA margin of 8.9% for the year 2023. In Q1 2024, the Adjusted EBITA margin improved from 6.0% to 10.4% year on year.

The OEM business offers lighting components to the industry. The OEM business was previously part of the Digital Products division and is now set up as a standalone business.

Reflecting this shift and the reallocation of central costs to the businesses, the OEM business recorded sales of EUR 457 million with an Adjusted EBITA of EUR 43 million and an Adjusted EBITA margin of 9.4% for the year 2023. In Q1 2024, the Adjusted EBITA margin decreased from 9.6% to 8.8% year on year.

The Conventional business offers special lighting, digital projection, and lamp electronics. The Conventional business is similar to the former Conventional Products division.

Following the reallocation of central costs to the businesses, the Conventional business recorded sales of EUR 627 million with an Adjusted EBITA of EUR 127 million and an Adjusted EBITA margin of 20.3% for the year 2023. In Q1 2024, the Adjusted EBITA margin decreased from 22.3% to 17.6% year on year.

'Other' represents amounts not allocated to the businesses and now mainly includes costs related to ventures, exploratory research and audits. Following the implementation of the new structure, part of the central costs has been reallocated to the four vertically integrated businesses. As a result of the reallocation, 'Other' Adjusted EBITA for 2023 reduced from EUR -86 million to EUR -31 million.

1 This document contains certain non-IFRS financial measures and ratios, such as comparable sales growth, EBITA, adjusted EBITA, and related ratios, which are not recognized measures of financial performance or liquidity under IFRS. All reported data are unaudited.
2 Please refer to appendix A for a visual representation of how the organizational structure has changed.

For further information, please contact:
Signify Investor Relations
Thelke Gerdes
Tel: +31 6 1801 7131
E-mail: thelke.gerdes@signify.com

Signify Corporate Communications
Tom Lodge
Tel: +31 6 5252 5416

E-mail: tom.lodge@signify.com

About Signify
Signifyproducts, Interactsystems and data-enabled services, deliver business value and transform life in homes, buildings and public spaces. In 2023, we had sales of EUR 6.7 billion, approximately 32,000 employees and a presence in over 70 countries. We unlock the extraordinary potential of light for brighter lives and a better world. We have been in the Dow Jones Sustainability World Indexsince our IPO for seven consecutive years and have achieved the EcoVadisPlatinum rating for four consecutive years, placing Signify in the top one percentof companies assessed. News from Signify can be found in the Newsroom,on X, LinkedInand Instagram. Information for investors is located on the Investor Relationspage.

Attachment

  • 20240614_Signify publishes comparable financials for 2023 and Q1 2024 (https://ml-eu.globenewswire.com/Resource/Download/86a15939-7a80-43b6-914b-cd8a363b5230)

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.